REGN

Regeneron Pharmaceuticals
D

REGN

560.19
USD
5.11
(0.92%)
مغلق
حجم التداول
32,863
الربح لكل سهم
36
العائد الربحي
0.32
P/E
14
حجم السوق
59,373,105,134
أصول ذات صلة
AMGN
AMGN
-0.02
(-0.01%)
284.68 USD
BIIB
BIIB
-1.730
(-1.34%)
127.690 USD
BMY
BMY
0.550
(1.23%)
45.365 USD
GILD
GILD
0.050
(0.05%)
110.350 USD
INCY
INCY
0.575
(0.74%)
78.230 USD
MRK
MRK
0.940
(1.18%)
80.380 USD
PFE
PFE
0.313
(1.31%)
24.250 USD
VRTX
VRTX
-9.99
(-2.59%)
375.66 USD
المزيد
الأخبار المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).